- Long-term endocrine therapy (ET) is associated with neither cognitive deficits nor impairment in women with hormone receptor (HR)-positive breast cancer (BCa).
Why this matters
- Previous studies of shorter duration found worse cognition.
- This was the longest prospective cohort.
- Findings should be reassuring to women receiving ET.
- Prospective Mind Body Study of women receiving ET (n=63) vs no ET (n=126) for HR+ BCa.
- Neuropsychological test battery covering 6 domains (including learning, memory, and attention) performed at baseline, 6 months, and 12 months and at 3-6 years.
- Impairment defined by test scores that were less than −1.5 or less than −2 z score, according to the International Cognition and Cancer Task Force guidelines.
- Funding: NIH.
- Mean follow-up, 4.3 years.
- There was no main effect of ET (vs no ET) on learning (P=.12), memory (P=.28), attention (P=.96), visuospatial (P=.28), executive function (P=.97), or processing speed (P=.15), after adjusting for age, IQ, depression, race, and chemotherapy exposure.
- No interaction of ET by time (baseline, 6-month, 12-month, and 3-6-year visits) for any of the domains listed here.
- ET (vs no ET) was not associated with impairment at 6 months (P=.36), 12 months (P=.80), or 3-6 years (P=.53).
- Observational design.
- Uncertain generalizability because of mostly white, highly educated participants.